Download our White Paper

InSilico white_book_mockup@2x

Content of the case study


What are in silico clinical trials?

The COVID-19 crisis is accelerating the adoption of new technologies and the pandemic is likely to change the face of human clinical trials: the time is right for biotechs and pharma companies to adopt clinical trials simulation.

Running in silico clinical trials with virtual patients is an opportunity for the industry to drive its R&D programs forward, unleash the power of better decision-making and help bring to market life-changing therapies for patients.


What are the applications?

In silico trialshas become a key strategic area of development over the past two years, with the support of the FDA and meet the needs of the industry which is looking for more efficient, less expensive drug development approaches.

Biotech & pharma companies are leveraging in silico modeling to de-risk trials for patients, help better understand biology and increase chances of success.


How does it work?

In silico is emerging as the 3rd pillar of the drug R&D paradigm, in support of - not a full substitute to -  more conventional in vitro and in vivo exploration and evidence-generation techniques.

NOVA’s modeling expertise combines mathematical models of diseases and treatments with virtual patients into an integrated clinical trial simulation platform called Jinkō®. to simulate in the same conditions as in vivo (same endpoints and clinical outcomes on a virtual population).